Third parties are typically a company’s main sources of exposure to legal, financial, reputational and strategic risks–and compliance officers are responsible for identifying and managing them...
Companies rely on global third parties and suppliers to deliver their products and services, but these third parties are increasingly becoming their main exposure to risk. In recent years, ten trends have...
Companies rely on third parties and suppliers around the world to deliver their products and services efficiently and effectively. But these third parties are also becoming a company’s main exposure...
Why is third party risk now at the top of a company’s agenda? Ten trends have come together to bring third party risk management to a tipping point. Seven of them are already in effect, such as global...
A due diligence checklist takes you step-by-step through the information you need to consider to help carry out a thorough investigation when you’re contemplating a new commercial relationship, a...
The Nexis Diligence+ solution goes beyond just public records or sanctions, combining sophisticated technology with a more comprehensive collection of global data to deliver in-depth, 360-degree assessments...
Due Diligence
Patient safety, clinical trial management, mergers and acquisitions, research and development, sales and marketing, and pricing structures are all areas where failure to conduct due diligence and mitigate risk effectively can lead to reputational damage, financial loss, and regulatory enforcement action. In just a couple of decades, the pharmaceuticals and life sciences industry has changed beyond recognition in response to globalization and demand for new products. What does the current risk landscape look like for pharmaceuticals and life sciences sector?